Vera Therapeutics, Inc. (NASDAQ:VERA) Stock Has Consensus Target Price of $76.86

Vera Therapeutics, Inc. (NASDAQ:VERA) has been given an average recommendation of “Moderate Buy” by the fifteen analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $76.86.

Several equities analysts have recently issued reports on VERA shares. Leerink Partners initiated coverage on Vera Therapeutics in a research report on Monday, October 12th. They set a “market perform” rating and a $34.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Vera Therapeutics in a research note on Friday, October 23rd. Raymond James Financial reissued a “strong-buy” rating on shares of Vera Therapeutics in a research note on Monday, October 26th. Guggenheim boosted their price objective on shares of Vera Therapeutics from $56.00 to $76.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Finally, JPMorgan Chase & Co. upped their target price on shares of Vera Therapeutics from $76.00 to $83.00 and gave the company an “overweight” rating in a research note on Tuesday, September 8th.

Insider Buying and Selling at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $37.00, for a total value of $684,500.00. Following the completion of the transaction, the chief executive officer owned 235,244 shares of the company’s stock, valued at $8,704,028. The trade was a 7.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Vera Therapeutics

A number of large investors have recently made changes to their positions in VERA. Sterling Capital Management LLC lifted its holdings in shares of Vera Therapeutics by 841.5% during the 3rd quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock valued at $68,000 after purchasing an additional 1,885 shares in the last quarter. Nykredit A S bought a new stake in Vera Therapeutics during the 2nd quarter worth approximately $97,000. Fulcrum Asset Management LLP bought a new stake in Vera Therapeutics during the 3rd quarter worth approximately $74,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Vera Therapeutics during the 3rd quarter worth approximately $119,000. Finally, Strs Ohio acquired a new stake in Vera Therapeutics during the 1st quarter worth approximately $249,000. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Stock Performance

Shares of Vera Therapeutics stock opened at $31.97 on Monday. The firm has a fifty day moving average of $31.83 and a two-hundred day moving average of $36.84. The stock has a market capitalization of $2.30 billion, a price-to-earnings ratio of -5.46 and a beta of 1.07. Vera Therapeutics has a 52 week low of $23.05 and a 52 week high of $56.05. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.92 and a current ratio of 10.92.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($1.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.58) by $0.06. During the same period in the prior year, the business earned ($1.20) earnings per share. As a group, equities research analysts predict that Vera Therapeutics will post -6.45 EPS for the current year.

About Vera Therapeutics

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company’s research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.

Vera’s lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases.